0.3791
price down icon1.46%   -0.0056
after-market アフターアワーズ: .38 0.0009 +0.24%
loading
前日終値:
$0.3847
開ける:
$0.3852
24時間の取引高:
4.53M
Relative Volume:
0.78
時価総額:
$127.57M
収益:
$52.29M
当期純損益:
$-134.84M
株価収益率:
-0.5055
EPS:
-0.75
ネットキャッシュフロー:
$-117.11M
1週間 パフォーマンス:
+3.58%
1か月 パフォーマンス:
-10.80%
6か月 パフォーマンス:
-35.26%
1年 パフォーマンス:
-66.45%
1日の値動き範囲:
Value
$0.3621
$0.3927
1週間の範囲:
Value
$0.3621
$0.41
52週間の値動き範囲:
Value
$0.3621
$1.40

Sangamo Therapeutics Inc Stock (SGMO) Company Profile

Name
名前
Sangamo Therapeutics Inc
Name
セクター
Healthcare (1113)
Name
電話
(510) 970-6000
Name
住所
501 CANAL BLVD., RICHMOND, CA
Name
職員
183
Name
Twitter
@sangamotx
Name
次回の収益日
2025-05-02
Name
最新のSEC提出書
Name
SGMO's Discussions on Twitter

SGMO を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
SGMO
Sangamo Therapeutics Inc
0.3791 129.45M 52.29M -134.84M -117.11M -0.75
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.17 120.98B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
771.25 80.15B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ARGX
Argen X Se Adr
864.42 51.56B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
354.75 47.74B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ONC
Beone Medicines Ltd Adr
336.16 37.38B 4.98B 69.59M 525.67M 0.5197

Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-11-07 ダウングレード Barclays Overweight → Equal Weight
2024-12-13 アップグレード Truist Hold → Buy
2024-12-10 繰り返されました H.C. Wainwright Buy
2023-11-03 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2023-04-28 ダウングレード BofA Securities Neutral → Underperform
2023-02-27 アップグレード Wedbush Neutral → Outperform
2023-01-06 ダウングレード BofA Securities Buy → Neutral
2022-06-13 再開されました Wedbush Neutral
2021-05-04 開始されました RBC Capital Mkts Outperform
2021-01-07 再開されました Guggenheim Neutral
2021-01-06 開始されました Stifel Hold
2020-12-16 再開されました H.C. Wainwright Buy
2020-09-08 開始されました BofA Securities Buy
2020-07-07 開始されました SunTrust Buy
2019-08-26 開始されました H.C. Wainwright Buy
2018-11-14 ダウングレード JP Morgan Overweight → Neutral
2018-11-09 ダウングレード Guggenheim Buy → Neutral
2018-10-10 開始されました Guggenheim Buy
2018-06-20 開始されました BofA/Merrill Buy
2017-11-15 アップグレード Piper Jaffray Neutral → Overweight
2017-06-22 再開されました Jefferies Buy
2016-11-01 ダウングレード Wedbush Outperform → Neutral
2016-10-19 ダウングレード Piper Jaffray Overweight → Neutral
2015-12-04 開始されました Wells Fargo Outperform
2015-10-23 再開されました Jefferies Buy
2013-05-03 開始されました BioLogic Equity Research Sell
2011-02-23 繰り返されました JMP Securities Mkt Outperform
2010-07-29 繰り返されました Wedbush Outperform
2009-10-19 開始されました Brean Murray Sell
2009-10-07 繰り返されました Leerink Swann Outperform
2009-08-25 繰り返されました JMP Securities Mkt Outperform
すべてを表示

Sangamo Therapeutics Inc (SGMO) 最新ニュース

pulisher
Jan 27, 2026

Dow Update: Is Sangamo Therapeutics Inc a strong growth stock2025 Market WrapUp & Long Hold Capital Preservation Tips - baoquankhu1.vn

Jan 27, 2026
pulisher
Jan 23, 2026

How The Pulled Price Target Is Reshaping The Story For Sangamo Therapeutics (SGMO) - Yahoo Finance

Jan 23, 2026
pulisher
Jan 22, 2026

Genome Editing Market Forecast to Reach $23.6 Billion by 2031 Registering 16.6% CAGR: Insights Into Technology and Investment Trends - GlobeNewswire Inc.

Jan 22, 2026
pulisher
Jan 21, 2026

Aug Selloffs: Does Sangamo Therapeutics Inc have a sustainable dividendWeekly Stock Analysis & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn

Jan 21, 2026
pulisher
Jan 20, 2026

Insider Sell: Whats the outlook for FRSXs sectorWeekly Market Summary & Safe Swing Trade Setup Alerts - baoquankhu1.vn

Jan 20, 2026
pulisher
Jan 19, 2026

Analysts Expect Breakeven For Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Before Long - simplywall.st

Jan 19, 2026
pulisher
Jan 18, 2026

Does Sangamo Therapeutics Inc. have pricing powerEntry Point & Low Drawdown Momentum Trade Ideas - bollywoodhelpline.com

Jan 18, 2026
pulisher
Jan 13, 2026

Published on: 2026-01-14 05:13:16 - Bộ Nội Vụ

Jan 13, 2026
pulisher
Jan 12, 2026

Fabry Disease Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, AVROBIO, 4D Molecular Therapeutics - Barchart.com

Jan 12, 2026
pulisher
Jan 12, 2026

Sangamo Therapeutics (SGMO) Shares Stabilize Amid Recent Key Pipeline Update - Finviz

Jan 12, 2026
pulisher
Jan 10, 2026

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat

Jan 10, 2026
pulisher
Jan 09, 2026

Can Sangamo Therapeutics Inc. stock attract ESG capital inflowsEarnings Growth Report & High Accuracy Buy Signal Tips - Улправда

Jan 09, 2026
pulisher
Jan 09, 2026

Is Sangamo Therapeutics Inc. stock oversold or undervaluedWeekly Trend Recap & Daily Growth Stock Investment Tips - Улправда

Jan 09, 2026
pulisher
Jan 08, 2026

Why Sangamo Therapeutics Inc. stock remains resilient2025 Momentum Check & Community Shared Stock Ideas - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

Can Sangamo Therapeutics Inc. stock weather global recessionOptions Play & Long-Term Growth Portfolio Plans - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

Surprises Report: How Sangamo Therapeutics Inc. stock compares to industry benchmarksJuly 2025 Technicals & Consistent Profit Trade Alerts - ulpravda.ru

Jan 08, 2026
pulisher
Jan 08, 2026

Is Sangamo Therapeutics Inc. stock a contrarian buyMarket Trend Review & Long-Term Growth Stock Strategies - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

Can Sangamo Therapeutics Inc. stock sustain market leadership2025 Volume Leaders & AI Optimized Trade Strategies - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

Inflation Data: How Sangamo Therapeutics Inc. stock compares to industry benchmarks2025 Dividend Review & High Win Rate Trade Tips - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

How Sangamo Therapeutics Inc. stock performs in weak economy2025 Risk Factors & Weekly High Momentum Picks - ulpravda.ru

Jan 08, 2026
pulisher
Jan 08, 2026

How resilient is Sangamo Therapeutics Inc. stock in market downturnsJuly 2025 WrapUp & Low Drawdown Trading Techniques - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

Will Sangamo Therapeutics Inc. (GBY) stock benefit from infrastructure billMarket Weekly Review & AI Forecast Swing Trade Picks - Улправда

Jan 08, 2026
pulisher
Jan 06, 2026

Is Sangamo Therapeutics Inc. stock attractive for retirement portfoliosFootwear buying guidance for outdoor walking and light jogging focuses on support for wide feet, making it a smart choice when deciding what to buy. - ulpravda.ru

Jan 06, 2026
pulisher
Jan 06, 2026

Will Sangamo Therapeutics Inc. stock reach Wall Street targets2026 world cup usa national team final top scorers possession football expert forecast preview - Улправда

Jan 06, 2026
pulisher
Jan 04, 2026

Sangamo Therapeutics (HAM:GBY) 9-Day RSI : 29.67 (As of Jan. 05, 2026) - GuruFocus

Jan 04, 2026
pulisher
Jan 04, 2026

Q3 2025 Sangamo Therapeutics Inc Earnings Call Transcript - GuruFocus

Jan 04, 2026
pulisher
Jan 04, 2026

Sangamo Therapeutics Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript - GuruFocus

Jan 04, 2026
pulisher
Jan 04, 2026

Sangamo Therapeutics (HAM:GBY) Preferred Stock - GuruFocus

Jan 04, 2026
pulisher
Jan 04, 2026

Sangamo Therapeutics Inc (HAM:GBY) DCF Valuation - GuruFocus

Jan 04, 2026
pulisher
Jan 04, 2026

Sangamo Therapeutics Inc Stock Baskets - GuruFocus

Jan 04, 2026
pulisher
Jan 04, 2026

Sangamo Therapeutics (HAM:GBY) Intrinsic Value: Projected F - GuruFocus

Jan 04, 2026
pulisher
Jan 03, 2026

Sangamo rises after trial data for Fabry disease therapy - MSN

Jan 03, 2026
pulisher
Jan 03, 2026

H.C. Wainwright Maintains Buy Rating on Sangamo Therapeutics (SGMO) - MSN

Jan 03, 2026
pulisher
Dec 31, 2025

Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates - sharewise.com

Dec 31, 2025
pulisher
Dec 21, 2025

Sangamo Therapeutics Stock Jump Looks Great, But How Secure Is That Gain? - Trefis

Dec 21, 2025
pulisher
Dec 20, 2025

Why Sangamo Therapeutics Inc. stock could outperform in 2025Oil Prices & High Return Trade Guides - Улправда

Dec 20, 2025
pulisher
Dec 20, 2025

Revenue Check: Can Sangamo Therapeutics Inc. stock surprise with earnings upsideJobs Report & Expert Approved Momentum Ideas - moha.gov.vn

Dec 20, 2025
pulisher
Dec 19, 2025

Sangamo Starts Putting BLA for Fabry Disease Gene Therapy Isa-Vec in Front of FDA - CGTLive®

Dec 19, 2025
pulisher
Dec 19, 2025

Growth Value: How Sangamo Therapeutics Inc. stock trades before earningsJuly 2025 PostEarnings & High Conviction Buy Zone Alerts - Улправда

Dec 19, 2025
pulisher
Dec 19, 2025

How Sangamo Therapeutics Inc. stock trades before earningsJuly 2025 Gainers & Weekly Consistent Profit Watchlists - Улправда

Dec 19, 2025
pulisher
Dec 18, 2025

Sangamo initiates rolling BLA submission for Fabry disease gene therapy By Investing.com - Investing.com Nigeria

Dec 18, 2025
pulisher
Dec 18, 2025

Sangamo Therapeutics initiates rolling submission of BLA to U.S. FDA - marketscreener.com

Dec 18, 2025
pulisher
Dec 18, 2025

Sangamo (SGMO) Begins BLA Submission for Promising Fabry Disease Therapy - GuruFocus

Dec 18, 2025
pulisher
Dec 18, 2025

Sangamo initiates rolling BLA submission for Fabry disease gene therapy - Investing.com India

Dec 18, 2025
pulisher
Dec 18, 2025

Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease - The Manila Times

Dec 18, 2025
pulisher
Dec 18, 2025

Single-dose gene therapy for rare Fabry disease moves toward FDA review - Stock Titan

Dec 18, 2025
pulisher
Dec 16, 2025

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Rating of "Hold" by Analysts - MarketBeat

Dec 16, 2025
pulisher
Dec 15, 2025

Sangamo Therapeutics Earnings Notes - Trefis

Dec 15, 2025
pulisher
Dec 13, 2025

Sangamo reports positive Fabry disease gene therapy results - MSN

Dec 13, 2025
pulisher
Dec 12, 2025

How the Narrative Surrounding Sangamo Therapeutics Is Shifting After New Regulatory and Valuation Signals - Yahoo Finance

Dec 12, 2025
pulisher
Dec 12, 2025

Book value per share of Sangamo Therapeutics, Inc. – SWB:GBY - TradingView — Track All Markets

Dec 12, 2025

Sangamo Therapeutics Inc (SGMO) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$99.82
price up icon 2.09%
$103.47
price up icon 0.87%
$34.40
price up icon 2.78%
$119.34
price up icon 1.14%
$162.64
price up icon 1.83%
biotechnology ONC
$336.16
price down icon 0.48%
大文字化:     |  ボリューム (24 時間):